



OPEN ACCESS

- YOUR ACCOUNT
- [Update your registration details](#)
- [Update your areas of interest](#)
- [Modify your password](#)
- YOUR ORDERS
- [Order to be completed](#)
- [Completed orders](#)
- SHOPPING BASKET
- Items: 0
- Total amount: € 0,00
- [Order details and checkout](#)
- HOW TO ORDER
- [Journals](#)
- [Books](#)
- YOUR SUBSCRIPTIONS
- [Activate](#)
- [View](#)
- [Contact subscription department](#)
- YOUR ARTICLES
- [View](#)
- YOUR EBOOKS
- [View](#)
- COUPON
- [Enable your coupon](#)
- ACCESSIBILITY
- [Standard viewing](#)
- [Larger font](#)
- [Text only](#)
- [High-contrast layout](#)

RASSEGNA

**Biochimica Clinica 2026 Giugno;50(2):117-29**


DOI: [10.23736/S0393-0564.26.00097-X](#)  
Copyright © 2026 Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - Medicina di Laboratorio  
language: English

**The gut microbiota-diabetes axis: mechanisms, modulation, and therapeutic perspectives**  
Jutishna BORA <sup>1</sup>, Smita LATA <sup>1</sup>, Anjali KUMARI <sup>1</sup>, Swati PRIYA <sup>1</sup>, Indrani BARMAN <sup>2</sup>, Sagar MONDAL <sup>2</sup>, Archana DHASMANA <sup>3</sup>, Sarvesh RUSTAGI <sup>4</sup>, Shailendra THAPLIYAL <sup>5</sup>, Ravi K. DESHWAL <sup>6</sup>, Sumira MALIK <sup>1,7</sup>   
<sup>1</sup> Amity Institute of Biotechnology, Amity University Jharkhand, Ranchi, India; <sup>2</sup> Faculty of Paramedical Sciences, Assam Down Town University, Assam, India; <sup>3</sup> Himalayan School of Biosciences, Swami Rama University, Dehradun, India; <sup>4</sup> Department of Food Technology, School of Agriculture, Maya Devi University, Dehradun, India; <sup>5</sup> School of Agriculture, Uttaranchal University, Dehradun, India; <sup>6</sup> Institute of Bioscience and Technology, Shri Ramswaroop Memorial University, Uttar Pradesh, India; <sup>7</sup> University Center for Research and Development (UCRD) Chandigarh University, NH-05 Chandigarh- Ludhiana Highway, Sahibzada Ajit Singh Nagar, India

HTML PDF

The gut microbiota (GM) is recognized as a major regulator of the host's metabolic processes, immune responses, and metabolic equilibrium. Recent studies have shown that changes in the composition of GM are closely related to diabetes mellitus, encompassing both type 1 (T1DM) and type 2 diabetes (T2DM). Dysbiosis, generally marked by decreased microbial diversity, shifts in the *Firmicutes/Bacteroidetes* ratio, and loss of key short-chain fatty acid (SCFA)-producing bacteria, has been shown to contribute to impaired glucose metabolism, heightened insulin resistance, and persistent low-level inflammation. Recent research has identified several microbial metabolites and components, including SCFAs, lipopolysaccharides (LPS), and trimethylamine N-oxide (TMAO), as potential early indicators for predicting disease and improving risk assessment. These compounds affect metabolic health through complex mechanisms, including modulation of gut barrier integrity and immune signaling. Some interventions aimed at restoring gut microbial balance have gained attention and are becoming a complementary method for managing diabetes. Approaches include supplementation with probiotics and prebiotics, dietary modifications that support beneficial taxa, fecal microbiota transplantation (FMT), and emerging microbiome engineering techniques. Recent studies, both from experimental and clinical research, suggest that microbiota-based therapies may improve and enhance diagnostic accuracy, leading to the development of tailored treatments for diabetes. This narrative review aims to summarize the recent evidences of the literature in the topic.

KEY WORDS: Gastrointestinal microbiome; Diabetes mellitus; Dysbiosis; Fecal microbiota transplantation



- JOURNAL TOOLS
- [Journal policies](#)
- [Publishing options](#)
- [eTOC](#)
- [To subscribe](#)
- [Submit an article](#)
- [Recommend to your librarian](#)

- ARTICLE TOOLS
- [Publication history](#)
- [Reprints](#)
- [Permissions](#)
- [Cite this article as](#)
- [Share](#)

